- Home
- EML vs FENC Comparison
EML vs FENC Comparison
Compare EML & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- FENC
- Stock Information
- Founded
- EML 1858
- FENC 1996
- Country
- EML United States
- FENC United States
- Employees
- EML N/A
- FENC N/A
- Industry
- EML Industrial Machinery/Components
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- FENC Health Care
- Exchange
- EML Nasdaq
- FENC Nasdaq
- Market Cap
- EML 161.7M
- FENC 156.9M
- IPO Year
- EML N/A
- FENC 2001
- Fundamental
- Price
- EML $23.51
- FENC $5.15
- Analyst Decision
- EML
- FENC Strong Buy
- Analyst Count
- EML 0
- FENC 2
- Target Price
- EML N/A
- FENC $14.00
- AVG Volume (30 Days)
- EML 6.8K
- FENC 127.4K
- Earning Date
- EML 05-05-2025
- FENC 05-13-2025
- Dividend Yield
- EML 1.87%
- FENC N/A
- EPS Growth
- EML N/A
- FENC N/A
- EPS
- EML N/A
- FENC N/A
- Revenue
- EML $272,751,967.00
- FENC $47,538,000.00
- Revenue This Year
- EML N/A
- FENC $2.68
- Revenue Next Year
- EML N/A
- FENC $71.63
- P/E Ratio
- EML $11.13
- FENC N/A
- Revenue Growth
- EML 5.37
- FENC 123.69
- 52 Week Low
- EML $23.15
- FENC $3.96
- 52 Week High
- EML $35.03
- FENC $11.11
- Technical
- Relative Strength Index (RSI)
- EML 32.83
- FENC 30.59
- Support Level
- EML $23.16
- FENC $5.10
- Resistance Level
- EML $25.71
- FENC $6.90
- Average True Range (ATR)
- EML 0.62
- FENC 0.33
- MACD
- EML -0.25
- FENC -0.15
- Stochastic Oscillator
- EML 9.78
- FENC 1.17
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.